

**Human Reference Antisera to Influenza A/Indonesia/05/2005 (H5N1), Low Titer**

**Catalog No. NR-33667**

This reagent is the property of the U.S. Government.

**For research use only. Not for human use.**

**Contributor:**

National Institutes of Allergy and Infectious Diseases, National Institutes of Health

**Manufacturer:**

Sanofi Pasteur

**Product Description:**

NR-33667 consists of pooled polyclonal antisera from humans immunized intramuscularly with two doses of an inactivated monovalent subvirion investigational influenza vaccine, A/Indonesia/05/2005 PR8-IBCDC-RG2 (H5N1) (clade 2.1.3).<sup>1</sup>

**Material Provided:**

Each vial contains 1 mL of pooled antisera.

**Packaging/Storage:**

NR-33667 is provided frozen and should be stored at -70°C or colder immediately upon arrival.

**Citation:**

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Human Reference Antiserum to Influenza A/Indonesia/05/2005 (H5N1), Low Titer, NR-33667."

**Biosafety Level: 1**

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see [www.cdc.gov/biosafety/publications/bmbl5/index.htm](http://www.cdc.gov/biosafety/publications/bmbl5/index.htm).

Universal Precautions should be used when handling biological materials derived from human sources, such as NR-33667.

**Disclaimers:**

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA

is available on our Web site at [www.beiresources.org](http://www.beiresources.org).

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

**Use Restrictions:**

**This material is distributed for internal research, non-commercial purposes only.** This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

**References:**

1. Belshe, R. B., et al. "Safety and Immunogenicity of Influenza A H5 Subunit Vaccines: Effect of Vaccine Schedule and Antigenic Variant." *J. Inf. Dis.* 203 (2011): 666-673. PubMed: 21282194.

ATCC® is a trademark of the American Type Culture Collection.

